Skip to content
  • Sunday, 26 July 2026
  • 1:45 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • European Commission Approves Expanded Use of Crysvita (burosumab) for Infants with X-Linked Hypophosphatemia
Pharmaceutical R&D

European Commission Approves Expanded Use of Crysvita (burosumab) for Infants with X-Linked Hypophosphatemia

Teuku Ryan Jul 23, 2026 0

Kyowa Kirin EMEA, a subsidiary of Kyowa Kirin, has secured a significant approval from the European Commission (EC) to broaden…

Read More
Pharmaceutical R&D

European Commission Approves AbbVie’s Aquipta (atogepant) for Acute Migraine Treatment

Teuku Ryan Jun 3, 2026 0

AbbVie has secured a significant regulatory endorsement from the European Commission (EC) for Aquipta (atogepant), marking a pivotal expansion of…

Read More
Pharmaceutical R&D

European Commission Approves Keytruda Combination Therapy for PD-L1-Positive Platinum-Resistant Ovarian Cancer

Teuku Ryan Apr 6, 2026 0

The European Commission (EC) has granted approval for Keytruda (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, as a…

Read More
The Rise of Agentic AI Coding Platforms: Empowering a New Generation of App DevelopersBD, Wellstar connect pharmacy-to-bedside medication management with AIScience News: A Century of Illuminating the Frontiers of KnowledgeCMS Launches Sweeping Anti-Fraud Initiative, Targeting Genetic Testing Spending and Soliciting Lab Industry Input for Future Regulations
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ